Yun Wu1, Weibo Cai, Xiaoyuan Chen. 1. Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University School of Medicine, 1201 Welch Rd, P095, Stanford, CA 94305-5484, USA.
Abstract
PURPOSE: Cell adhesion molecule integrin alpha v beta 3 is an excellent target for tumor interventions because of its unique expression on the surface of several types of solid tumor cells and on almost all sprouting tumor vasculatures. Here, we describe the development of near-infrared (NIR) fluorochrome Cy7-labeled RGD peptides for tumor integrin targeting. PROCEDURES: Mono-, di-, and tetrameric RGD peptides were synthesized and conjugated with Cy7. The integrin specificity of these fluorescent probes was tested in vitro for receptor binding assay and fluorescence microscopy and in vivo for subcutaneous U87MG tumor targeting. RESULTS: The tetrameric RGD peptide probe with the highest integrin affinity showed the highest tumor activity accumulation and strongest tumor-to-normal tissue contrast. This uptake is integrin-specific as the signal accumulated in the tumor can be effectively blocked by unconjugated RGD peptide antagonist of integrin alpha v beta 3. CONCLUSIONS: Noninvasive NIR fluorescence imaging is able to detect and semiquantify tumor integrin expression based upon the highly potent tetrameric RGD peptide probe.
PURPOSE: Cell adhesion molecule integrin alpha v beta 3 is an excellent target for tumor interventions because of its unique expression on the surface of several types of solid tumor cells and on almost all sprouting tumor vasculatures. Here, we describe the development of near-infrared (NIR) fluorochrome Cy7-labeled RGD peptides for tumor integrin targeting. PROCEDURES: Mono-, di-, and tetrameric RGD peptides were synthesized and conjugated with Cy7. The integrin specificity of these fluorescent probes was tested in vitro for receptor binding assay and fluorescence microscopy and in vivo for subcutaneous U87MG tumor targeting. RESULTS: The tetrameric RGD peptide probe with the highest integrin affinity showed the highest tumor activity accumulation and strongest tumor-to-normal tissue contrast. This uptake is integrin-specific as the signal accumulated in the tumor can be effectively blocked by unconjugated RGD peptide antagonist of integrin alpha v beta 3. CONCLUSIONS: Noninvasive NIR fluorescence imaging is able to detect and semiquantify tumor integrin expression based upon the highly potent tetrameric RGD peptide probe.
Authors: J S Reynolds; T L Troy; R H Mayer; A B Thompson; D J Waters; K K Cornell; P W Snyder; E M Sevick-Muraca Journal: Photochem Photobiol Date: 1999-07 Impact factor: 3.421
Authors: Xiaoyuan Chen; Shuang Liu; Yingping Hou; Michel Tohme; Ryan Park; James R Bading; Peter S Conti Journal: Mol Imaging Biol Date: 2004 Sep-Oct Impact factor: 3.488
Authors: P C Brooks; S Strömblad; L C Sanders; T L von Schalscha; R T Aimes; W G Stetler-Stevenson; J P Quigley; D A Cheresh Journal: Cell Date: 1996-05-31 Impact factor: 41.582
Authors: Xiaoyuan Chen; Yingping Hou; Michel Tohme; Ryan Park; Vazgen Khankaldyyan; Ignacio Gonzales-Gomez; James R Bading; Walter E Laug; Peter S Conti Journal: J Nucl Med Date: 2004-10 Impact factor: 10.057
Authors: Nrusingh C Biswal; John K Gamelin; Baohong Yuan; Marina V Backer; Joseph M Backer; Quing Zhu Journal: J Biomed Opt Date: 2010 Jan-Feb Impact factor: 3.170
Authors: Roshni Iyer; Tam Nguyen; Dona Padanilam; Cancan Xu; Debabrata Saha; Kytai T Nguyen; Yi Hong Journal: J Control Release Date: 2020-02-12 Impact factor: 9.776
Authors: Robert Shenkar; Palamadai N Venkatasubramanian; Alice M Wyrwicz; Jin-cheng Zhao; Changbin Shi; Amy Akers; Douglas A Marchuk; Issam A Awad Journal: Neurosurgery Date: 2008-10 Impact factor: 4.654
Authors: Jing Cui; David Maberley; Arif Samad; Patrick Ma; Allison Ning; Joanne A Matsubara; Peter Baciu Journal: J Ocul Biol Dis Infor Date: 2009-02-24